Chongqing Primary Aldosteronism Study
Study Details
Study Description
Brief Summary
We intends to conduct a series of original clinical research about PA, and establish a large cohort of PA and essential hypertension patients with long-term follow-up of cardiovascular events, renal end points etc. We will establish a large sample of blood, urine, adrenal tissue of the subjects, and the genomics,metabonomics, proteomics database, to explore the mechanism of the PA and target organ damage, risk factors, diagnostic methods and biomarkers.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This study will include the subjects of a series of studies on hypertension conducted by our team, including essential hypertension, PA subjects, and establish a large sample database and specimen bank through follow-up and omics analysis.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Primary aldosteronism screened, confirmed and subtyped according to the guidelines. |
Other: no intervention
no intervention
|
| Essential hypertension screened for PA and excluded the diagnosis of PA as well as other secondary hypertesion |
Other: no intervention
no intervention
|
Outcome Measures
Primary Outcome Measures
- numbers of patients who develop cardiovascular events [1-15 years]
compare the long-term cardiovascular and cerebrovascular events in patients with primary aldosteronism and essential hypertension
Secondary Outcome Measures
- estimated glomerular filtration rate (eGFR) [1-15 years]
Compare the incidence of hypertensive nephropathy between two groups (based on eGFR)
- The incidence of new atrial fibrillation [1-15 years]
Compare the occurrence of new atrial fibrillation between patients with primary aldosteronism and essential hypertension
- The incidence of left ventricular hypertrophy [1-15 years]
Compare the occurrence of left ventricular hypertrophy between patients with primary aldosteronism and essential hypertension
- the variation of carotid intima-media thickness [1-15 years]
Compare the occurrence of the variation of carotid intima-media thickness between patients with primary aldosteronism and essential hypertension
- subgroup analysis of cardiovascular events [1-15 years]
Compare the cardiovascular and cerebrovascular risk between unilateral PA and idiopathic bilateral adrenal hyperplasia
- quality of life score [1-15 years]
Compare the quality of life between unilateral PA and idiopathic bilateral adrenal hyperplasia by the questionnaire.
- Cardiovascular risk score [1-15 years]
To investigate what kind of cardiovascular risk score can better predict cardiovascular risk of PA
Eligibility Criteria
Criteria
Inclusion Criteria:
-
hypertensive patients who completed ARR screening and necessary further tests;
-
Voluntary to sign the informed consent.
Exclusion Criteria:
-
patients with severe cardiac, hepatic or renal dysfunction;
-
suspicious or confirmed other types of secondary hypertension, including Cushing's syndrome, pheochromocytoma and renal artery stenosis et al.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Qifu Li | Chongqing | Chongqing | China | 400016 |
Sponsors and Collaborators
- Chongqing Medical University
Investigators
- Study Chair: Qifu Li, phD, First Affiliated Hospital of Chongqing Medical University
Study Documents (Full-Text)
None provided.More Information
Publications
- Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, Gabetti L, Mengozzi G, Williams TA, Rabbia F, Veglio F, Mulatero P. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol. 2017 Apr 11;69(14):1811-1820. doi: 10.1016/j.jacc.2017.01.052.
- Stowasser M, Gordon RD. Primary Aldosteronism: Changing Definitions and New Concepts of Physiology and Pathophysiology Both Inside and Outside the Kidney. Physiol Rev. 2016 Oct;96(4):1327-84. doi: 10.1152/physrev.00026.2015. Review.
- Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, Satoh F, Amar L, Quinkler M, Deinum J, Beuschlein F, Kitamoto KK, Pham U, Morimoto R, Umakoshi H, Prejbisz A, Kocjan T, Naruse M, Stowasser M, Nishikawa T, Young WF Jr, Gomez-Sanchez CE, Funder JW, Reincke M; Primary Aldosteronism Surgery Outcome (PASO) investigators. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017 Sep;5(9):689-699. doi: 10.1016/S2213-8587(17)30135-3. Epub 2017 May 30.
- CONPASS